A Phase 1, Open-label Study to Evaluate the Effect of Lapatinib, a BCRP Inhibitor, on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Receiving Hemodialysis

Trial Profile

A Phase 1, Open-label Study to Evaluate the Effect of Lapatinib, a BCRP Inhibitor, on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Receiving Hemodialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2016

At a glance

  • Drugs JTZ 951 (Primary) ; Lapatinib
  • Indications Anaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Akros Pharma
  • Most Recent Events

    • 27 Apr 2016 Status changed from recruiting to completed.
    • 24 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top